The influence of drug-like concepts on decision-making in medicinal chemistry
The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.
Abstract
The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development. However, despite this acceptance, analysis of recent trends reveals that the physical properties of molecules that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compounds in clinical development. The consequences of the marked increase in lipophilicity--the most important drug-like physical property--include a greater likelihood of lack of selectivity and attrition in drug development. Tackling the threat of compound-related toxicological attrition needs to move to the mainstream of medicinal chemistry decision-making.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“(Note that liophilicity per se may not be relevant, as drugs require carriers to cross membranes [18], and promiscuity and off-target effects increase with lipophilicity [1679].)”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1679]
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420 · cited 1×
“Overall oral bioavailability depends not just on absorption but also on dissolution, gut transit time and first-pass metabolism, so it is perhaps surprising that rat bioavailability can be categorized by simple physical properties such as PSA and rotatable bond”
BackgroundLead- and drug-like compounds: the rule-of-five revolution
Lipinski, C. A. (2004) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2004.11.007 · Cited by 6,199 · cited 1×
“jpg" NDATA ITEM> ]> Ten years have passed since the publication of the 'rule of five' physical property guidelines for drug permeabilit”
BackgroundCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Budavari, S. (1998) · Royal Society of Chemistry eBooks · Cited by 2,741
ADMET in silico modelling: towards prediction paradise?
van de Waterbeemd, H., & Gifford, E. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1032 · Cited by 1,863
Martin, Y. C. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0492002 · Cited by 1,020 · cited 1×
“, and number of rule-of-five violations, PSA and ionization stat”
BackgroundQuantitative approach to biochemical structure-activity relationships
Hansch, C. (1969) · Accounts of Chemical Research · doi:10.1021/ar50020a002 · Cited by 918 · cited 1×
“This is not surprising: the role of LogP in influencing drug potency, pharmacokinetics and toxicity has been established for many year”
BackgroundMolecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery
Hann, M. M., Leach, A. R., & Harper, G. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci000403i · Cited by 877 · cited 1×
“This allows the processes of chemical optimization, which frequently increase physical propertie”
Background
Research works printed but not linked: 3
- Kubinyi, H. Lipophilicity and biological activity. Drug transport and drug distribution in model systems and in biological systems. Arzn. Forsch. 29, 1067–1080 (1979).
- Wood, A. Annual Reports in Medicinal Chemistry Volume 41 503–522 (Academic Press, Burlington, 2006).
- Gray, N. Changing Landscapes: A Special Report on the World's Top 50 Pharma Companies. Pharmaceutical Executive web site [online] , (2006)
Cited by
Fluorine in medicinal chemistry
Purser, S., Moore, P. R., Swallow, S., & Gouverneur, V. (2008) · Chem. Soc. Rev. · doi:10.1039/b610213c · Cited by 7,570
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
The Medicinal Chemist’s Toolbox: An Analysis of Reactions Used in the Pursuit of Drug Candidates
Roughley, S. D., & Jordan, A. M. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200187y · Cited by 2,725
Rings in Drugs: Miniperspective
Taylor, R. D., MacCoss, M., & Lawson, A. D. G. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4017625 · Cited by 2,543
Quantifying the chemical beauty of drugs
Bickerton, G. R., Paolini, G. V., Besnard, J., Muresan, S., & Hopkins, A. L. (2012) · Nature Chemistry · doi:10.1038/nchem.1243 · Cited by 2,242
“The complete weighted QED is given in equation (4), where W is the weighting for each respective desirability function:”
Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore
Fleming, F. F., Yao, L., Ravikumar, P. C., Funk, L., & Shook, B. C. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100762r · Cited by 1,754
A Review on Recent Advances in Nitrogen-Containing Molecules and Their Biological Applications
Kerru, N., Gummidi, L., Maddila, S., Gangu, K. K., & Jonnalagadda, S. B. (2020) · Molecules · doi:10.3390/molecules25081909 · Cited by 1,716
The ChEMBL bioactivity database: an update
Bento, A. P., Gaulton, A., Hersey, A., Bellis, L. J., Chambers, J., Davies, M., Krüger, F. A., Light, Y., Mak, L., McGlinchey, S., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1031 · Cited by 1,492
Escape from Flatland 2: complexity and promiscuity
Lovering, F. (2013) · MedChemComm · doi:10.1039/c2md20347b · Cited by 1,444
An analysis of the attrition of drug candidates from four major pharmaceutical companies
Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., et al. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4609 · Cited by 1,450
Self-citationThe ErbB/HER family of protein-tyrosine kinases and cancer
Roskoski, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.002 · Cited by 1,353
Principles and Applications of Halogen Bonding in Medicinal Chemistry and Chemical Biology
Wilcken, R., Zimmermann, M. O., Lange, A., Joerger, A. C., & Boeckler, F. M. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3012068 · Cited by 1,331
EASL Clinical Practice Guidelines: Drug-induced liver injury
Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.014 · Cited by 1,276
“Lipophilicity (often measured as the log of octanol-water partition coefficient, LogP) is known to influence various drugrelated aspects such as potency, pharmacokinetics and toxicity.(120,121) Drugs with higher lipophilicity appear to have increased off-target binding as well as an increased likelihood of causing tox…”
BackgroundThe role of ligand efficiency metrics in drug discovery
Hopkins, A. L., Keserü, G. M., Leeson, P. D., Rees, D. C., & Reynolds, C. H. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4163 · Cited by 1,181
Self-citationThe Current State of Peptide Drug Discovery: Back to the Future?
Henninot, A., Collins, J. C., & Nuss, J. M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00318 · Cited by 1,113
Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100008c · Cited by 1,063
Profound Methyl Effects in Drug Discovery and a Call for New CH Methylation Reactions
Schönherr, H., & Cernak, T. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201303207 · Cited by 1,094
Plant-Derived Natural Products: A Source for Drug Discovery and Development
Chaachouay, N., & Zidane, L. (2024) · Drugs and Drug Candidates · doi:10.3390/ddc3010011 · Cited by 1,081
“Furthermore, the sustainable and organic characteristics of plant-based chemicals are in line with the current focus on ecologically responsible pharmaceutical research, using the renewable resources provided by plants [72].”
BackgroundConcepts of Artificial Intelligence for Computer-Assisted Drug Discovery
Yang, X., Wang, Y., Byrne, R., Schneider, G., & Yang, S. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00728 · Cited by 1,022
Ritchie, T. J., & Macdonald, S. J. F. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.07.014 · Cited by 901
“Catalyzed by Lipinski’s seminal ‘rule of five’ for absorption and permeability [1], there is now a substantial body of literature describing property space occupied by orally bioavailable smallmolecule drugs [ 2 ,3].”
BackgroundInfluentialSchneider, G. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.232 · Cited by 910
The influence of lipophilicity in drug discovery and design
Arnott, J. A., & Planey, S. L. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.714363 · Cited by 868
“However, compounds that achieve their potency through lipophilic interactions are likely to be less selective and more promiscuous, running the risk of off-target interactions and unwanted toxicity [8,13].”
BackgroundResultInfluentialLipophilicity in drug discovery
Waring, M. J. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441003605098 · Cited by 873
“Evidence for increased promiscuity with high lipophilicity was provided by an analysis of a set of 2,133 drugs and reference compounds from the Cerep Bioprint database, carried out by Leeson and Springthrope, that showed that promiscuity increases dramatically for logP > 3 [9].”
BackgroundMethodStructure and dynamics of molecular networks: A novel paradigm of drug discovery
Csermely, P., Korcsmáros, T., Kiss, H. J. M., London, G., & Nussinov, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.016 · Cited by 892
“Leeson and Springthorpe (2007) warned that systematic deviations from these rules may have a dangerous impact on drug design, increasing late-attritions due to side-effects and/or toxicity.”
BackgroundLarge-scale prediction and testing of drug activity on side-effect targets
Lounkine, E., Keiser, M. J., Whitebread, S., Mikhailov, D., Hamon, J., Jenkins, J. L., Lavan, P., Weber, E., Doak, A. K., Côté, S., et al. (2012) · Nature · doi:10.1038/nature11159 · Cited by 881
Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.013 · Cited by 835
The rise of fragment-based drug discovery
Murray, C. W., & Rees, D. C. (2009) · Nature Chemistry · doi:10.1038/nchem.217 · Cited by 791
Review: biologically active pyrazole derivatives
Ansari, A., Ali, A., Asif, M., & Shamsuzzaman, S. (2017) · New Journal of Chemistry · doi:10.1039/c6nj03181a · Cited by 786
Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles
Wischke, C., & Schwendeman, S. P. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.04.042 · Cited by 790
Reducing safety-related drug attrition: the use of in vitro pharmacological profiling
Bowes, J., Brown, A. J., Hamon, J., Jarolimek, W., Sridhar, A., Waldron, G., & Whitebread, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3845 · Cited by 748
Bioisosteres of the Phenyl Ring: Recent Strategic Applications in Lead Optimization and Drug Design
Subbaiah, M. A. M., & Meanwell, N. A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01215 · Cited by 710
A perspective on multi‐target drug discovery and design for complex diseases
Ramsay, R. R., Popovic‐Nikolic, M. R., Nikolic, K., Uliassi, E., & Bolognesi, M. L. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0181-2 · Cited by 718
“4): 2–5] facilitate transport through BBB [76], while higher lipophilicity increase plasma protein binding, decrease solubility in plasma, and rise metabolic and toxicity risks of the agents [77].”
BackgroundZhou, Y., Zhang, Y., Lian, X., Li, F., Wang, C., Zhu, F., Qiu, Y., & Chen, Y. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkab953 · Cited by 665
Molecular Recognition in Chemical and Biological Systems
Persch, E., Dumele, O., & Diederich, F. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201408487 · Cited by 654
The impact of natural products upon modern drug discovery
Ganesan, A. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.03.016 · Cited by 646
The blood-brain barrier: Physiology and strategies for drug delivery
Pandit, R., Chen, L., & Götz, J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.11.009 · Cited by 651
The influence of lead discovery strategies on the properties of drug candidates
Keserü, G. M., & Makara, G. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2796 · Cited by 628
Meanwell, N. A. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200211v · Cited by 620
Biophysical properties of the clinical-stage antibody landscape
Jain, T., Sun, T., Durand, S., Hall, A., Houston, N. R., Nett, J. H., Sharkey, B., Bobrowicz, B., Caffry, I., Yu, Y., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1616408114 · Cited by 629
“In fact, an analogous trend has been consistently observed for small-molecule drugs, whereby lipophilicity and molecular weight decrease with clinical advancement (27, 28), a trend also attributed in part to affect relative drug levels on target.”
BackgroundOxadiazoles in Medicinal Chemistry
Boström, J., Hogner, A., Llinàs, A., Wellner, E., & Plowright, A. T. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm2013248 · Cited by 614
Srinivasarao, M., & Low, P. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00013 · Cited by 605
Recent Developments in Fragment-Based Drug Discovery
Congreve, M., Chessari, G., Tisi, D., & Woodhead, A. J. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8000373 · Cited by 611
ESKAPEing the labyrinth of antibacterial discovery
Tommasi, R., Brown, D. G., Walkup, G. K., Manchester, J. I., & Miller, A. A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4572 · Cited by 608
Discovery of small molecule cancer drugs: Successes, challenges and opportunities
Hoelder, S., Clarke, P. A., & Workman, P. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.02.004 · Cited by 587
CNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure
Rankovic, Z. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501535r · Cited by 548
Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
Roskoski, R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.104609 · Cited by 559
Bioactive Benzofuran derivatives: A review
Khanam, H., & Shamsuzzaman (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.11.039 · Cited by 554
“Furthermore, compounds that contain heterocyclic moieties often exhibit improved solubilities and can facilitate salt formation properties, both of which are known to be important for oral absorption and bioavailability [8].”
BackgroundProperties of FDA-approved small molecule protein kinase inhibitors
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.006 · Cited by 554
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
“off-target effects increase with lipophilicity [1679].”
Probing the links between in vitro potency, ADMET and physicochemical parameters
Gleeson, M. P., Hersey, A., Montanari, D., & Overington, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3367 · Cited by 503
The application of in silico drug-likeness predictions in pharmaceutical research
Tian, S., Wang, J., Li, Y., Li, D., Xu, L., & Hou, T. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.009 · Cited by 498
N‐Methylation of Peptides and Proteins: An Important Element for Modulating Biological Functions
Chatterjee, J., Rechenmacher, F., & Kessler, H. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201205674 · Cited by 494
Put a ring on it: application of small aliphatic rings in medicinal chemistry
Bauer, M. R., Di Fruscia, P., Lucas, S. C. C., Michaelides, I. N., Nelson, J. E., Storer, R. I., & Whitehurst, B. C. (2021) · RSC Medicinal Chemistry · doi:10.1039/d0md00370k · Cited by 479
Wager, T. T., Chandrasekaran, R. Y., Hou, X., Troutman, M. D., Verhoest, P. R., Villalobos, A., & Will, Y. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100007x · Cited by 477
“broad ligand profiling assays (31), reactive metabolite”
Nanoparticle Hydrophobicity Dictates Immune Response
Moyano, D. F., Goldsmith, M., Solfiell, D. J., Landesman-Milo, D., Miranda, O. R., Peer, D., & Rotello, V. M. (2012) · Journal of the American Chemical Society · doi:10.1021/ja2108905 · Cited by 478
Polypharmacology – Foe or Friend?
Peters, J.-U. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400856t · Cited by 465
Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule?
Dobson, P. D., & Kell, D. B. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2438 · Cited by 475
“This is because many of the recent trends in molecular drug design and development have been towards increased lipophilicity, leading to a greater likelihood of both a lack of selectivity and of attritio”
BackgroundKhan, I., Ibrar, A., Abbas, N., & Saeed, A. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.02.005 · Cited by 469
Ritchie, T. J., Macdonald, S. J. F., Young, R. J., & Pickett, S. D. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2010.11.014 · Cited by 442
Orally Absorbed Cyclic Peptides
Nielsen, D. S., Shepherd, N. E., Xu, W., Lucke, A. J., Stoermer, M. J., & Fairlie, D. P. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00838 · Cited by 445
Erkizan, H. V., Kong, Y., Merchant, M., Schlottmann, S., Barber-Rotenberg, J. S., Yuan, L., Abaan, O. D., Chou, T.-H., Dakshanamurthy, S., Brown, M. L., et al. (2009) · Nature Medicine · doi:10.1038/nm.1983 · Cited by 452
“NSC635437 had a greater potential to chemical derivatization with favorable drug-like propertie”
Mäder, P., & Kattner, L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00960 · Cited by 438
Oxetanes in Drug Discovery: Structural and Synthetic Insights
Wuitschik, G., Carreira, E. M., Wagner, B., Fischer, H., Parrilla, I., Schuler, F., Rogers-Evans, M., & Müller, K. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm9018788 · Cited by 418
Schneider, N., Lowe, D. M., Sayle, R. A., Tarselli, M. A., & Landrum, G. A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00153 · Cited by 427
Poynton, F. E., Bright, S. A., Blasco, S., Williams, D. C., Kelly, J. M., & Gunnlaugsson, T. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00680b · Cited by 421
Edmondson, S. D., Yang, B., & Fallan, C. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.04.030 · Cited by 422
Constraining Cyclic Peptides To Mimic Protein Structure Motifs
Hill, T. A., Shepherd, N. E., Diness, F., & Fairlie, D. P. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201401058 · Cited by 418
Finding the sweet spot: the role of nature and nurture in medicinal chemistry
Hann, M. M., & Keserü, G. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3701 · Cited by 411
Use of Natural Products as Chemical Library for Drug Discovery and Network Pharmacology
Gu, J., Gui, Y., Chen, L., Yuan, G., Lu, H.-Z., & Xu, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062839 · Cited by 410
“The widely used concept of drug-like chemical space was important for drug discovery [23,39–44].”
Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update
Roskoski, R. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107059 · Cited by 383
“Leeson and Springthorpe re-ported that drug lipophilicity, as assessed by its – ALogP value, is a key property that should be monitored during drug development [100].”
Using the Golden Triangle to optimize clearance and oral absorption
Johnson, T. W., Dress, K. R., & Edwards, M. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.08.045 · Cited by 392
Lead‐Oriented Synthesis: A New Opportunity for Synthetic Chemistry
Nadin, A., Hattotuwagama, C., & Churcher, I. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201105840 · Cited by 390
What Do Medicinal Chemists Actually Make? A 50-Year Retrospective
Walters, W. P., Green, J., Weiss, J. R., & Murcko, M. A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200504p · Cited by 387
Biophysics in drug discovery: impact, challenges and opportunities
Renaud, J.-P., Chung, C.-W., Danielson, U. H., Egner, U., Hennig, M., Hubbard, R. E., & Nar, H. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.123 · Cited by 382
Lipophilic Efficiency as an Important Metric in Drug Design
Johnson, T. W., Gallego, R. A., & Edwards, M. P. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00077 · Cited by 349
In silico ADME/T modelling for rational drug design
Wang, Y., Xing, J., Xu, Y., Zhou, N., Peng, J., Xiong, Z., Liu, X., Luo, X., Luo, C., Chen, K., et al. (2015) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583515000190 · Cited by 367
“Consequently, these properties may a ff ect the ADME/T pro fi le of compounds, their potency, selectivity against targets, and the ‘ screenability ’ in high-throughput screening (HTS) (Leeson & Springthorpe, 2007).”
BackgroundBoyd, B. J., Bergström, C. A. S., Vinarov, Z., Kuentz, M., Brouwers, J., Augustijns, P., Brandl, M., Bernkop-Schnürch, A., Shrestha, N., Préat, V., et al. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.104967 · Cited by 367
“the organizational factor and last but not least, the lipophilic molecular requirements of contemporary targets (Bergström et al., 2016; Keserü and Makara, 2009; Leeson and Springthorpe, 2007; Leeson and StGallay, 2011; Vieth and Sutherland, 2006).”
BackgroundMolecular obesity, potency and other addictions in drug discovery
Hann, M. M. (2011) · MedChemComm · doi:10.1039/c1md00017a · Cited by 363
“The use of indices such as LE and LLE are particularly useful for this purpose.”
BackgroundInfluentialChen, M., Borlak, J., & Tong, W. (2013) · Hepatology · doi:10.1002/hep.26208 · Cited by 348
“It is reasonable to assume that high lipophilicity might augment in vivo toxicological outcome based on an increased off-target activity.(12,25) Overall, high dose and increased lipophilicity is an unfavorable combination.”
BackgroundLaverty, H., Benson, C., Cartwright, E., Cross, M., Garland, C., Hammond, T., Holloway, C., McMahon, N., Milligan, J., Park, B., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01255.x · Cited by 363
“, 2008; Frid and Matthews, 2010), making it very difficult for medicinal chemists to develop structure–activity relationships, although there are emerging data that suggest an association between physicochemical drug properties and in vivo or in vitro toxicological profiles (Krejsa et al., 2003; Leeson and Springthorp…”
BackgroundKell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361
“Developing novel pharmaceutical agents is a costly enter- prise, and many candidate drugs fall by the wayside during the development process (see e.g. Dobson et al. 2009b; Kola and Landis 2004; Leeson and Springthorpe 2007).”
BackgroundMethodZafrani, Y., Sod-Moriah, G., Yeffet, D., Berliner, A., Amir, D., Marciano, D., Elias, S., Katalan, S., Ashkenazi, N., Madmon, M., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00604 · Cited by 358
Lang, S. B., Wiles, R. J., Kelly, C. B., & Molander, G. A. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201709487 · Cited by 343
The significance of acid/base properties in drug discovery
Manallack, D. T., Prankerd, R. J., Yuriev, E., Oprea, T. I., & Chalmers, D. K. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35348b · Cited by 329
Howard, S., Berdini, V., Boulstridge, J. A., Carr, M. G., Cross, D. M., Curry, J., Devine, L. A., Early, T. R., Fazal, L., Gill, A. L., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm800984v · Cited by 333
The Thermodynamics of Protein–Ligand Interaction and Solvation: Insights for Ligand Design
Olsson, T. S. G., Williams, M. A., Pitt, W. R., & Ladbury, J. E. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.09.073 · Cited by 334
Alex, A., Millan, D. S., Perez, M., Wakenhut, F., & Whitlock, G. A. (2011) · MedChemComm · doi:10.1039/c1md00093d · Cited by 329
Waring, M. J. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.03.109 · Cited by 326
Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update
Roskoski, R. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105463 · Cited by 335
Huigens III, R. W., Morrison, K. C., Hicklin, R. W., Flood Jr, T. A., Richter, M. F., & Hergenrother, P. J. (2013) · Nature Chemistry · doi:10.1038/nchem.1549 · Cited by 320
Young, R. J., Green, D. V. S., Luscombe, C. N., & Hill, A. P. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.06.001 · Cited by 311
Lagorce, D., Bouslama, L., Becot, J., Miteva, M. A., & Villoutreix, B. O. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx491 · Cited by 317
“In general, when performing such computations, one aims at enhancing the chances of finding compounds with an acceptable absorption, distribution, metabolism, excretion and toxicity (ADMET) profile (Leeson, 2016; Leeson and Springthorpe, 2007).”
BackgroundAnti-HIV Drug Discovery and Development: Current Innovations and Future Trends: Miniperspective
Zhan, P., Pannecouque, C., De Clercq, E., & Liu, X. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00497 · Cited by 303
Barry, J., Fritz, M., Brender, J. R., Smith, P. E. S., Lee, D.-K., & Ramamoorthy, A. (2009) · Journal of the American Chemical Society · doi:10.1021/ja809217u · Cited by 313
Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update
Roskoski, R. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2022.106552 · Cited by 273
“Leeson and Springthorpe suggested that drug lipophilicity, as assessed by its – ALogP value, is one of the more important properties that should be monitored during drug development [96].”
BackgroundGoing further than Lipinski's rule in drug design
Walters, W. P. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.648612 · Cited by 306
“Studies of both patents and medicinal chemistry papers show that molecules continue to become more lipophilic [6,8].”
BackgroundA Data-Driven Approach to Predicting Successes and Failures of Clinical Trials
Gayvert, K. M., Madhukar, N. S., & Elemento, O. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2016.07.023 · Cited by 310
“The adoption of drug-likeness concepts early in the drug discovery process has been shown to reduce attrition rates (Leeson and Springthorpe, 2007).”
BackgroundChemical predictive modelling to improve compound quality
Cumming, J. G., Davis, A. M., Muresan, S., Haeberlein, M., & Chen, H. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4128 · Cited by 311
Targeting ERK1/2 protein-serine/threonine kinases in human cancers
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.039 · Cited by 308
Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition
Roskoski, R. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2012.11.007 · Cited by 303
Metadata
- Authors
- Leeson, P. D., & Springthorpe, B.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Leeson, Paul D.
- ORCID
- Leeson, Paul D.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-11
- Volume
- 6
- Issue
- 11
- Pages
- 881-890
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2062458432
- Cited by
- 2,403
- References
- 60
- Citations by year
- 2026: 143 · 2025: 113 · 2024: 140 · 2023: 127 · 2022: 104 · 2021: 144 · 2020: 105 · 2019: 146 · 2018: 119 · 2017: 140 · 2016: 145 · 2015: 140 · 2014: 151 · 2013: 160 · 2012: 165
- FWCI
- 6.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Merck
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- drug-likeness, Lipinski's rule of five, lipophilicity, drug attrition, drug discovery, drug selectivity
- MeSH terms
- Chemistry, Pharmaceutical, Decision Making, Pharmaceutical Preparations, Humans, Water, 1-Octanol
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.